Department of Dermatology and Allergy, Charité, Universitätsmedizin Berlin, Charitéplatz 1, Germany.
Pediatr Allergy Immunol. 2011 Feb;22(1 Pt 1):1-8. doi: 10.1111/j.1399-3038.2010.01120.x.
While there is increasing information about the pathogenesis and treatment of chronic spontaneous urticaria (csU) in adults, there is little published information about csU in children. Consequently, most of the recommendations contained in current guidelines for the prevention and treatment of csU in infants and children is based on extrapolation of data obtained in adults. To rectify this, this review points out critical gaps in our knowledge and suggests strategies which may help us to improve our understanding of this condition. How common is csU in children? What do we know about its clinical presentation and the presence of useful biomarkers? What are its common underlying causes? What is the course of csU in children? How does csU affect the everyday life of children? What treatment options are available for children? To answer these questions, two separate types of information are required. The first is information about the prevalence of the condition in the community at large and how csU affects the everyday life of both the child-patient and the parent or carer. Because most csU cases in infants and children do not come to specialists but are treated by general practitioners or by parents using over-the-counter medications, these questions may be answered only by general population surveys or schools programmes. The second is clinical information including family history and disease presentation, the presence of biomarkers and comorbidities, objective measures of severity, frequency and duration of exacerbations, the response to therapy and the time to remission. Targeted questionnaires need to be developed and validated for these investigations. This has already begun in Germany with the establishment of the CU-KID Netzwerk (Email address: cu-kid@charite.de), the aim of which is to identify clinical centres and colleagues who treat children with urticaria and to initiate the information gathering described above.
虽然关于成人慢性自发性荨麻疹(csU)的发病机制和治疗方法的信息越来越多,但关于儿童 csU 的信息却很少。因此,目前关于婴儿和儿童 csU 预防和治疗的指南中包含的大多数建议都是基于从成人中获得的数据推断得出的。为了纠正这一问题,本综述指出了我们知识中的关键空白,并提出了一些策略,这些策略可能有助于我们更好地了解这种疾病。儿童中 csU 有多常见?我们对其临床表现和有用生物标志物的存在了解多少?它的常见根本原因是什么?儿童 csU 的病程如何?csU 如何影响儿童的日常生活?有哪些可供儿童使用的治疗选择?要回答这些问题,需要两种类型的信息。第一种是关于该病在整个社区中的流行情况以及 csU 如何影响儿童患者及其父母或照顾者的日常生活的信息。由于大多数婴儿和儿童的 csU 病例不会去看专家,而是由全科医生或父母使用非处方药物治疗,因此这些问题可能只能通过对普通人群的调查或学校的项目来回答。第二种是包括家族史和疾病表现、生物标志物和合并症的存在、严重程度、发作频率和持续时间的客观测量、对治疗的反应以及缓解时间等在内的临床信息。需要为这些研究制定和验证针对性的问卷。这已经在德国开始了,建立了 CU-KID 网络(电子邮件地址:cu-kid@charite.de),其目的是确定治疗荨麻疹的儿童的临床中心和同事,并开始收集上述信息。